Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proline henggliflozin in diabetes after kidney transplantation
ChiCTR2500096542Phase 4Not yet recruiting
- Sponsor
- Eighth Medical Center of the People's Liberation Army General Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in post-transplantation diabetes mellitus (PTDM) and type 2 diabetes mellitus (T2DM), sponsored by Eighth Medical Center of the People's Liberation Army General Hospital. Primary endpoints: Time in range on continuous glucose monitoring, Fasting blood glucose and 2 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
post-transplantation diabetes mellitus (PTDM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500096542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096542.